CGRP and CGRP-Receptor as Targets of Migraine Therapy: Brain Prize-2021.

What It Covers

Researchers studied CGRP (Calcitonin Gene-Related Peptide) in the context of migraine in this meta-analysis publication.

The winners in 2021 were Lars Edvinsson, Peter Goadsby, Michael Moskowitz and Jes Olesen.

They are the fathers of migraine pathomechanism, which led to revolutionary new treatments.

This review summarizes their landmark findings.

Why It Was Studied

Migraine is a highly prevalent primary headache with an unclear pathomechanism.

During the last 40 years, numerous hypotheses have arisen; among them, the theory of the trigeminovascular system is the primary one.

How the Review Was Done

Data related to this topic were reviewed from PubMed records published between 1979 and May 2021.

Searches were based on preclinical and clinical studies in the covered field.

The findings were listed in chronological order.

From a therapeutic perspective, only randomized controlled trials and meta-analysis were discussed.

What Was Measured

Migraine is a highly prevalent primary headache with an unclear pathomechanism.

During the last 40 years, numerous hypotheses have arisen; among them, the theory of the trigeminovascular system is the primary one.

Topics PubMed links to this paper include Awards and Prizes, Brain, Calcitonin Gene-Related Peptide, Headache, Migraine Disorders and Receptors, Calcitonin Gene-Related Peptide.

The authors tagged it with the keywords Brain Prize, CGRP, monoclonal antibodies, neuropeptides and trigeminovascular system.

What This Means in Plain Language

This is a meta-analysis of CGRP (Calcitonin Gene-Related Peptide) in people with migraine.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (CNS & neurological disorders drug targets), a journal based in United Arab Emirates.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.